Agency is enthused about Part D's success, but critics say problems remain
THURSDAY, Jan. 31 (HealthDay News) -- The three-year-old Medicare Part D drug program is seeing the number of its enrollees climb, even as costs for the program fall, U.S. health officials announced Thursday.
"Overall, costs for beneficiaries and taxpayers are considerably lower than originally projections, enrollment continues to rise and customer satisfaction remains very high," Kerry Weems, acting administrator at the U.S. Centers for Medicare and Medicaid Services (CMS), told reporters.
But critics aren't so enthusiastic, with many still faulting the program for its complexity, its high co-pays on some drugs and its inability to negotiate lower prices with the drug industry.
According to Weems, the projected cost for Medicare part D is $117 billion lower over the next decade than experts estimated just last summer. "This means that over the 10-year period [from] 2008 to 2017, the estimated $915 billion cost of Part D fell to $798 billion," he said.
These reductions in costs are due to the slowing of price increases, lighter administrative costs and higher rebates from drug manufacturers, Weems added.
At the same time, he reported, after the third open enrollment period that ended in December, the plan now has an additional 1.5 million people.
"Overall, there are about 25.4 million people enrolled in Part D," Weems said.
And, he noted, "there are now 39.5 million people, most in Medicare, with some form of drug coverage."
When the new drug plan rolled out in 2006, health officials estimated that 43 million Americans would be eligible for some drug benefit.
Most people surveyed today -- more than 85 percent -- are satisfied with the plan, Weems noted.
But a critic was less than impressed by those numbers.
"The administration has set a pretty low bar fo
All rights reserved